Metagenomi Inc

NASDAQ: MGX
$6.46
-$0.01 (-0.2%)
Closing price May 7, 2024

MGX Chart and Intraday Price

MGX Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector TECHNOLOGY
Industry GENERAL
Address NONE
Fiscal Year End September
Latest Quarter None
Market Cap 0.00M USD
Metagenomi Inc is a pioneering biotech firm based in Emeryville, California, focusing on developing groundbreaking gene editing therapies. Leveraging a comprehensive suite of genome editing tools, including advanced nucleases and base editors, the company aims to revolutionize treatments for various diseases. Through strategic partnerships with industry leaders like ModernaTX and Affini-T Therapeutics, Metagenomi is at the forefront of creating innovative solutions for in vivo human therapies and cancer treatment. Founded in 2016, its commitment to leveraging metagenomics-derived technologies positions it as a key player in the biotechnology sector.

MGX Articles

A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.